Crossmark

Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia

Crossref DOI link: https://doi.org/10.1186/s12879-019-4741-5

Published Online: 2020-01-10

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tsertsvadze, Tengiz

Gamkrelidze, Amiran

Nasrullah, Muazzam

Sharvadze, Lali

Morgan, Juliette

Shadaker, Shaun

Gvinjilia, Lia

Butsashvili, Maia

Metreveli, David

Kerashvili, Vakhtang

Ezugbaia, Marina

Chkhartishvili, Nikoloz

Abutidze, Akaki

Kvaratskhelia, Valeri

Averhoff, Francisco
License Information

Text and Data Mining valid from 2020-01-10

Version of Record valid from 2020-01-10
More Information

Article History

Received: 17 April 2019

Accepted: 27 December 2019

First Online: 10 January 2020

Ethics approval and consent to participate

: The study was approved by the Institutional review board of the Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi.

: Not Applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below